Intermountain Ventures is investing in a startup that uses generative AI to predict biological outcomes.
The venture capital arm of the Salt Lake City-based health system participated in a series A financing round June 3 for Matterworks. The company plans to employ the funding to advance its machine learning and scientific operations.
“Matterworks is leveraging AI to unlock a new data layer for biology by making mass spectrometry accessible to all biologists,” said Craig Asher, managing director of participating venture capital firm OMX Ventures, in a news release.
